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We have investigated the in vitro effects of INCB024360
on dendritic cell maturation and activation of antigen-
specific T cells. INCB024360 is a novel inhibitor of
indoleamine-2, 3-dioxygenase (IDO), and is currently in
several ongoing clinical trials. INCB024360 effectively
suppresses systemic tryptophan catabolism and tumor
growth.
Human dendritic cells (DC) were generated from
PBMCs from healthy donors. The tryptophan (Trp) and
kynurenine (Kyn) concentrations in supernatants, and
the Trp/Kyn ratio, were measured by HPLC. The Trp
level was 75.8% in supernatants of immature DCs with
little breakdown to Kyn (Kyn/Trp ratio of 0.32). In con-
trast, in supernatants of matured DCs, the Kyn/Trp
ratio was 5.9 for IFNg matured DCs, and 9.2 for IFNg/
LPS matured DCs. Treatment with INCB024360
resulted in almost no breakdown of tryptophan. The
expression levels of several DC activation markers did
not change after treatment with INCB024360.
We then compared the efficacy of antigen presentation
by DCs treated with and without the inhibitor. MUC1-C
peptide specific CTL were derived from a prostate cancer
patient. DCs pulsed with peptide and treated with
INCB024360 stimulated the CTL to produce more IFNg
and other type I cytokines than untreated DCs.
A MUC1-C-specific, HLA-A24+ was stimulated using
its specific MUC1 peptide and DCs treated with
INCB024360. The T cells were used in a CTL assay using
PC3 (human prostate carcinoma, MUC1+, HLA-A24+) as
a target and ASPC-1 (human pancreatic carcinoma,
MUC1+, HLA-A24NEG) as a negative control. Pre-treating
the DCs with INCB024360 resulted in increased tumor
cell lysis. An additional T cell line, specific for brachyury
peptide and HLA-A2, was derived from another prostate
cancer patient, and after stimulation with INCB treated
DCs the lysis of the human breast cancer cell line
increased.
These results thus demonstrated that INCB024360
treatment of DCs resulted in both increased cytokine
production and increased tumor cell lysis by antigen-
specific CD8+ T cell lines derived from cancer patients.
This suggests that INCB024360 could potentially be
effectively combined with other immune modulating
therapies. Murine anti-tumor studies of INCB024360
alone or in combination with vaccine are ongoing.
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